|
The dedication of Talecris Biotherapeutics and Prolastin® to the alpha1 community is evident by our continuous commitment to developing new programs and services and our ongoing research to find ways to improve the lives of Alphas everywhere.
Programs and Services
Talecris Biotherapeutics has provided Prolastin®, along with funding and in-kind support, to professional and patient organizations since 1988. The wide variety of services Talecris offers, including grants to patient associations and researchers, continues to improve the lives of people with AAT deficiency.
 |
 |
|
Supports the Talecris AlphaKit Testing Program to expand diagnosis and awareness of AAT deficiency
|
|
|
|
Prolastin DirectSM provides information and tools to help patients manage their AAT deficiency
|
|
|
|
Provides ongoing funding and support of the Alpha-1 community through investments in research initiatives through the Alpha-1 Foundation
|
|
|
|
Continues to be a major contributor to the Alpha-1 Association patient activities and regional education days
|
|
|
|
Sponsors the Alpha-1 Foundation's Web sites |
Research and Development
Talecris Biotherapeutics' investment in research and technology is ongoing, with the goals of increasing product supply, further enhancing safety, and producing innovative products and delivery techniques. Building on our strength and experience, we are always improving manufacturing technologies.
|
|
|
Working to perfect new manufacturing technologies that will increase current production capacity, as well as develop new products to help improve the quality of life for people living with AAT deficiency
|
|
|
|
Talecris continues to lead the industry in pathogenic prion research* |
The Future
Talecris Biotherapeutics is dedicated to helping patients with AAT deficiency to lead independent and fulfilling lives. We will continue to show our support by expanding our commitment to programs and services for healthcare professionals, patients, and their families—in an effort to reach out to the entire AAT-deficient community.
Our endeavors include collaboration with professional and patient organizations and:
|
|
|
Disease awareness initiatives directed at the medical community
|
|
|
|
Efforts to improve screening and diagnosis of AAT-deficient patients
|
|
|
|
Education programs related to treatment and comprehensive disease management
|
|
|
|
Support for research to add to the body of knowledge about AAT deficiency specifically related to the benefits of Prolastin® therapy |
*A prion is a microscopic protein particle similar to a virus but lacking nucleic acid. A prion is likely the infectious agent responsible for scrapie and other degenerative diseases of the nervous system.
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|